Larimar Therapeutics, Inc. (LRMR) News
Filter LRMR News Items
LRMR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LRMR News Highlights
- LRMR's 30 day story count now stands at 2.
- Over the past 25 days, the trend for LRMR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about LRMR are MG and FA.
Latest LRMR News From Around the Web
Below are the latest news stories about LARIMAR THERAPEUTICS INC that investors may wish to consider to help them evaluate LRMR as an investment opportunity.
With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investorsKey Insights Given the large stake in the stock by institutions, Larimar Therapeutics' stock price might be vulnerable... |
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsCompleted full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups.Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial now expected in Q1 2024, refined from H1 2024Initiation of open label extension (OLE) trial with 25 mg daily dosing of nomlabofusp remains on track for Q1 2024; |
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology ConferenceBALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023. Details on the fireside chat can be |
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of DirectorsBALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company’s Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in |
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma ConferenceBALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023. Details on the panel discussion can be found below. Title: Rare Neurological DiseasesDat |
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsInitiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial’s 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalen |
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2mQuite a few insiders have dramatically grown their holdings in Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) over the past... |
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say AnalystsSince the beginning of January, we’ve seen a steady rise in the stock markets. The NASDAQ is up 35% so far this year, and the S&P 500 has gained 19%. There has clearly been a shift in investor sentiment, away from last year’s bear market. The shift makes sense. The annualized rate of inflation peaked at 9.1% last June, fell to 6.5% by December, and has since fallen further. The June 2023 data showed annualized inflation at just 3%. Additionally, Goldman Sachs currently assesses the probability o |
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension TrialTop-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024Company management hosting a webcast and conference call today at 8:00 a.m. ET BALA CYNWYD, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatm |
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical OfficerBALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell “Rusty” Clayton, DO, as Chief Medical Officer (“CMO”), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. “We are delighted to welcome Dr. Clayton in his ne |